Retrospective analysis of plasma exchange combined with glucocorticosteroids for the treatment of systemic lupus erythematosus-related acute pancreatitis in central China

被引:7
作者
Yu, Yi-kai [1 ]
Yu, Fei [1 ]
Ye, Cong [1 ]
Dai, Yu-jie [1 ]
Huang, Xiao-wei [2 ]
Hu, Shao-xian [1 ]
机构
[1] Huangzhong Univ Sci & Technol, Dept Rheumatol & Immunol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China
[2] Huangzhong Univ Sci & Technol, Tongji Hosp, Dept Digest Med, Tongji Med Coll, Wuhan 430030, Peoples R China
关键词
systemic lupus erythematosus; acute pancreatitis; plasma exchange; IL-6; serum lipid; PLASMAPHERESIS; SLE; INTERLEUKIN-6; METAANALYSIS; PATIENT; DISEASE;
D O I
10.1007/s11596-016-1615-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Systemic lupus erythematosus-related acute pancreatitis (SLEAP) has a poor prognosis with a high mortality. We described the clinical features of SLEAP, and discussed the feasibility of plasma exchange (PE) combined with glucocorticosteroids (GC) in short-term prognosis and possible mechanism in reducing serum inflammatory cytokine IL-6 and removing serum lipids. A retrospective study was performed by an independent rheumatologist. Medical records of SLEAP from March 2010 to December 2014 were retrieved from Tongji Hospital information system, and patients were divided into two groups according to whether PE therapy was adopted. Sixteen patients treated with PE in combination with GC were classified as group A, and the other 10 patients who were treated with merely GC were classified as group B. Patients' clinical remission rate and average daily GC dosage after two-week therapy were compared between the two groups. Patients' serum inflammatory cytokines and lipid concentration were compared between baseline and after two-week treatment in both groups. Pearson correlation test was performed to determine association between serum cytokines and Ranson score. SLEDAI score in group A patients at baseline (14.8 +/- 3.1) showed no statistical difference from that in group B (14.1 +/- 3.3). At baseline serum IL-6 levels had no significant difference between group A [13.14 (11.12, 16.57) mg/L] and group B [14.63 (11.37, 16.37) mg/L]; after two-week therapy IL-6 decreased significantly in group A [9.16 (7.93, 10.75)mg/L] while it did not show decreasing trend in group B [13.62 (9.29,17.63) mg/L]. Serum lipid concentration after two-week therapy in group A [(TC=5.02 +/- 0.53, TG=1.46 +/- 0.44) mmol/L] decreased significantly compared to baseline [(TC=6.11 +/- 0.50, TG=2.14 +/- 1.03) mmol/L], while similar tendency was not observed in group B. The remission rate after two-week therapy was higher in group A (70.0%) than in group B (25.0%). Acute pancreatitis (AP) was one of the clinical manifestations of active SLE. PE combined with GC could reduce serum IL-6 level, and remove serum lipid to improve short-term prognosis. Therefore, it might be a safe and effective way in treating SLEAP and was worth continuing to explore its feasibility.
引用
收藏
页码:501 / 508
页数:8
相关论文
共 32 条
[1]   Diagnostic Accuracy of Interleukin-6 and Interleukin-8 in Predicting Severe Acute Pancreatitis: A Meta-Analysis [J].
Aoun, Elie ;
Chen, Joy ;
Reighard, Derek ;
Gleeson, Ferga C. ;
Whitcomb, David C. ;
Papachristou, Georgios I. .
PANCREATOLOGY, 2009, 9 (06) :777-785
[2]   Sequential monitoring of serum IL-6, TNF-α, and IFN-γ levels in a CAEBV patient treated by plasma exchange and immunochemotherapy [J].
Arai, Ayako ;
Nogami, Ayako ;
Imadome, Ken-Ichi ;
Kurata, Morito ;
Murakami, Naomi ;
Fujiwara, Shigeyoshi ;
Miura, Osamu .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (05) :669-673
[3]   Practice guidelines in acute pancreatitis [J].
Banks, Peter A. ;
Freeman, Martin L. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (10) :2379-2400
[4]   Lupus-associated pancreatitis [J].
Breuer, Gabriel S. ;
Baer, Asher ;
Dahan, David ;
Nesher, Gideon .
AUTOIMMUNITY REVIEWS, 2006, 5 (05) :314-318
[5]   Increased Expression of Ganglioside GM1 in Peripheral CD4+T Cells Correlates Soluble Form of CD30 in Systemic Lupus Erythematosus Patients [J].
Dong, Lingli ;
Hu, Shaoxian ;
Chen, Fang ;
Lei, Xiaomei ;
Tu, Wei ;
Yu, Yikai ;
Yang, Liu ;
Sun, Wei ;
Yamaguchi, Takuro ;
Masaki, Yasufumi ;
Umehara, Hisanori .
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2010,
[6]   Why and how should we measure disease activity and damage in lupus? [J].
Feld, Joy ;
Isenberg, David .
PRESSE MEDICALE, 2014, 43 (06) :E151-E156
[7]   Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients [J].
Fitz Gerald, JD ;
Grossman, JM .
LUPUS, 1999, 8 (08) :638-644
[8]   SYSTEMIC LUPUS-ERYTHEMATOSUS - A CASE-REPORT WITH UNUSUAL MANIFESTATIONS AND FAVORABLE OUTCOME AFTER PLASMAPHERESIS [J].
GARCIACONSUEGRA, J ;
MERINO, R ;
ALONSO, A ;
GODED, F .
EUROPEAN JOURNAL OF PEDIATRICS, 1992, 151 (08) :581-582
[9]   ACUTE-PANCREATITIS - AN EARLY MANIFESTATION OF SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
HUANG, JL ;
HUANG, CC ;
CHEN, CY ;
HUNG, IJ .
PEDIATRIC EMERGENCY CARE, 1994, 10 (05) :291-293
[10]  
Ikura Y, 2000, J RHEUMATOL, V27, P2715